Is Enveda profitable in 2026?

Enveda has not disclosed audited revenue or profitability. It raised a $150M Series D on September 4, 2025 reaching unicorn status (~$1B valuation), and its value rests on pipeline progress, not disclosed earnings.

Could AI replace Enveda's drug discovery process?

No general AI model can replicate Enveda's core asset: a proprietary library of over 1 million characterized natural compounds and over 1 billion mass spectra feeding its PRISM model, plus wet lab robotics and FDA INDs built since 2019.

Who are Enveda's biggest competitors?

Recursion Pharmaceuticals, Insilico Medicine, Isomorphic Labs and Xaira Therapeutics compete in AI drug discovery. Isomorphic Labs raised a $2.1B Series B by May 2026, far exceeding Enveda's $150M Series D from September 2025.

Enveda is privately held and venture backed, with no IPO filed as of the brief date. Investors include Lux Capital, Kinnevik, Premji Invest, Sanofi and Microsoft, following a $150M Series D that closed September 4, 2025.

What is Enveda's most important upcoming milestone?

Enveda's lead candidate ENV-294 for atopic dermatitis has Phase 2a and Phase 2b trials ongoing, with additional data expected at the EADV Congress in Vienna on October 1, 2026, a key catalyst for its roughly $1B valuation.

Has Enveda had layoffs?

No layoffs have been reported. Headcount rose from about 250 employees in late 2024 to roughly 380 to 389 by June 2026, a 27% year over year increase, alongside continued senior clinical hiring in April 2026.

United States · United States

Enveda

AI-driven drug discovery company mining natural compounds for new medicines.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from Oct 2026 · Every call on the record Checkpoint: ENV-294 Phase 2a/2b efficacy and safety data presented at EADV Congress, Vienna

The call

Enveda's path depends less on AI rivals and more on whether ENV-294's Phase 2 data proves its spectra-to-medicine platform actually works.

Enveda is a biotech company that uses artificial intelligence and robotic labs to discover new medicines from natural compounds like plants and fungi. It has built up a huge private library of over one million cataloged natural materials and billions of data points from lab tests that competitors and general AI systems cannot easily copy or recreate.

Why

AI pressure: None apparent. General AI models can't replicate Enveda's proprietary spectra library; here AI powers their PRISM model, not a threat to it. Could AI do the core job? Unlikely.

Bigger players: Sanofi, Pfizer, Lilly, Novartis. Big pharma could build in-house AI discovery platforms, but so far they invest and partner instead, as Sanofi did in 2025. Could a giant copy it? No, they are blocked.

What protects it. A library of over 1 million characterized natural compounds and 1 billion mass spectra, plus wet-lab robots and FDA-cleared trials.

What would change this call

ENV-294 Phase 2a/2b readout at EADV Congress Vienna around Oct 1, 2026. Shows whether Enveda's AI-discovered candidate is clinically effective and safe.
Terms and valuation of Enveda's next fundraise after Phase 2 data. Shows whether investors still trust the platform after clinical results.
Progress of ENV-6946 (IBD) and ENV-308 (obesity) into Phase 1 readouts. Shows whether Enveda can de-risk beyond its lead asset with a broader pipeline.

Key numbers

$150M Series D closed, ~$1B valuation (2025-09-04)
PRISM model trained on over 1B mass spectra (2024-06)
~380-389 employees, up 27% year over year (2026-06-20)

Named risks

ENV-294 Phase 2a/2b readout due around Oct 1, 2026 could fail or show safety signal, undercutting valuation. Severity: high
Lead indication atopic dermatitis is crowded with Dupixent, JAK inhibitors and other oral IL-4/13 programs. Severity: medium
No disclosed audited revenue means continued reliance on venture funding rounds. Severity: medium
~$1B valuation rests on unproven clinical pipeline rather than commercial revenue. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Isomorphic Labs	gaining on	Raised $2.1B Series B by May 2026, far outpacing Enveda's $150M Series D from Sep 2025
Insilico Medicine	gaining on	Already has a Phase II AI-designed asset (2023) and an Eli Lilly partnership as of Nov 2025
Recursion Pharmaceuticals	contesting	Public via 2024 Exscientia merger, ~$1B raised, competing in AI small-molecule discovery
Sanofi, Pfizer, Lilly, Novartis	contesting	Big pharma choosing to partner or invest (Sanofi joined Series C Feb 2025) rather than build rival platforms

Questions people ask

Is Enveda profitable in 2026?: Enveda has not disclosed audited revenue or profitability. It raised a $150M Series D on September 4, 2025 reaching unicorn status (~$1B valuation), and its value rests on pipeline progress, not disclosed earnings.
Could AI replace Enveda's drug discovery process?: No general AI model can replicate Enveda's core asset: a proprietary library of over 1 million characterized natural compounds and over 1 billion mass spectra feeding its PRISM model, plus wet lab robotics and FDA INDs built since 2019.
Who are Enveda's biggest competitors?: Recursion Pharmaceuticals, Insilico Medicine, Isomorphic Labs and Xaira Therapeutics compete in AI drug discovery. Isomorphic Labs raised a $2.1B Series B by May 2026, far exceeding Enveda's $150M Series D from September 2025.
Who owns Enveda?: Enveda is privately held and venture backed, with no IPO filed as of the brief date. Investors include Lux Capital, Kinnevik, Premji Invest, Sanofi and Microsoft, following a $150M Series D that closed September 4, 2025.
What is Enveda's most important upcoming milestone?: Enveda's lead candidate ENV-294 for atopic dermatitis has Phase 2a and Phase 2b trials ongoing, with additional data expected at the EADV Congress in Vienna on October 1, 2026, a key catalyst for its roughly $1B valuation.
Has Enveda had layoffs?: No layoffs have been reported. Headcount rose from about 250 employees in late 2024 to roughly 380 to 389 by June 2026, a 27% year over year increase, alongside continued senior clinical hiring in April 2026.

Timeline

2026-07-23ENV-294 Phase 1b data presented at AAD Innovation Academy; EADV Congress slot accepted for Oct 1, 2026
2026-04-15Christopher Porter appointed Senior VP of Clinical Operations
2026-03-31Positive Phase 1b results reported for ENV-294 in moderate to severe atopic dermatitis
2025-09-04Closed $150M Series D, reached unicorn status (~$1B valuation), Mikael Dolsten joins board
2025-02-26Sanofi joins Series C, bringing total Series C financing to $150M
2024-11First AI-discovered candidate advanced to clinical trials; $130M Series C closed
2024-06-14Announced $55M Series B2 and Microsoft collaboration on PRISM foundation model
2021-06Closed $51M Series A led by Lux Capital
2019Founded by Viswa Colluru and Pieter Dorrestein

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.